A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

INTERVENTION: investigational material(s) Generic name etc : LY2216684 INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational material : LY2216684 12 mg or 18 mg QD in tablet form orally. Placebo QD in tablet form orally. CONDITION: Major Depressive disoder INCLUSION CRITERIA: Male and female ,adult outpatients aged>=18 years To Meet DSM‐IV‐TR diagnostic criteria for MDD assessed by the Mini‐International Neuropsychiatric Interview (MINI) Partial response to a course of SSRI treatment and the SSRI treatment must be at a stable Patients must have a score >=16 on the GRID 17‐Item Hamilton Depression Rating Scale (GRID‐HAMD17) total score